Company / Shareholders' Equity
Gain Therapeutics, Inc. Shareholders' Equity History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$12.6M
FY2024
5-year range
$6.2M / $34.8M
FY2021-FY2024
Trend
-33.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $35M to $13M over the past 2 years.
Based on SEC 10-K filings.
$13M in FY2024 with a 3-year CAGR of +26.6%.
Declined from $35M to $13M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +26.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +26.6%, indicating consistent growth.
- In FY2024, shareholders' equity decreased 33.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $12.6M | -33.4% |
| FY2023 | $18.9M | -45.8% |
| FY2022 | $34.8M | +461.4% |
| FY2021 | $6.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026